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The BAR (Bin/amphiphysin/Rvs) domain deﬁnes an emerging
superfamily of proteins implicated in fundamental biological
processes by sensing and inducing membrane curvature. We
identiﬁed a novel autoregulatory function for the BAR domain
of two related GAPs’ (GTPase-activating proteins) of the GRAF
(GTPase regulator associated with focal adhesion kinase) sub-
family. We demonstrate that the N-terminal fragment of these
GAPs including the BAR domain interacts directly with the GAP
domain and inhibits its activity. Analysis of various BAR and
GAP domains revealed that the BAR domain-mediated inhibition
of these GAPs’ function is highly speciﬁc. These GAPs, in
their autoinhibited state, are able to bind and tubulate liposomes
in vitro, and to generate lipid tubules in cells. Taken together,
we identiﬁed BAR domains as cis-acting inhibitory elements
that very likely mask the active sites of the GAP domains and
thus prevent down-regulation of Rho proteins. Most remarkably,
these BAR proteins represent a dual-site system with separate
membrane-tubulation and GAP-inhibitory functions that operate
simultaneously.
Key words: autoregulation, autoinhibited state, Bin/amphiphysin/
Rvs (BAR) domain, GTPase-activating protein (GAP), GTP
hydrolysis, GTPase reaction, Rho protein family.
INTRODUCTION
Members of the Rho family of small guanine-nucleotide-binding
proteins are key regulatory molecules that couple changes in
the extracellular environment to intracellular signal transduction.
They act as intracellular molecular switches by cycling between
active (GTP-bound) and inactive (GDP-bound) states [1]. Activ-
ation of Rho proteins results in their association with effector
moleculesthatsubsequentlyactivateawidevarietyofdownstream
signalling cascades and regulate many important processes in all
eukaryotic cells, including motility and endocytic trafﬁcking [2].
The activity of Rho proteins – at a speciﬁc time and at a speciﬁc
siteinthecell–isstrictlycontrolledbythreeclassesofregulatory
proteins: the GDIs (guanine-nucleotide-dissociation inhibitors),
the GEFs (guanine-nucleotide-exchange factors) and the GAPs
(GTPase-activating proteins) [1]. These regulators safeguard two
distinct cycles: membrane/cytosol partition of the Rho proteins
and exchange/hydrolysis of the bound nucleotide.
TheGTP-hydrolysisreactionisafundamentalprocessinliving
cells and represents an important timer in intracellular processes.
The rate of Rho protein-mediated GTP hydrolysis is intrinsically
low. Direct interaction with GAPs speciﬁc for Rho proteins
accelerates the reaction by several orders of magnitude [3]. The
RhoGAP functions are critical for the termination of signal trans-
duction [4]. Thus mutations in genes encoding GAPs of the Rho
proteins have drastic consequences and underlie several human
diseases. OPHN1 (oligophrenin-1) mutations frequently cause
X-linked mental retardation that is associated with cerebellar
hypoplasia [5]. Another GAP that regulates endocytosis via the
CLIC (clathrin-independent carrier)/GEEC (glycosylphospha-
tidylinositol-enriched endosomal compartment) pathway [6] and
has been implicated as a tumour-suppressor gene of acute myelo-
genous leukaemia and myelodysplastic syndrome is GRAF1
(GTPase-regulator associated with focal adhesion kinase-1)
[7]. These RhoGAPs together with PSGAP [PH (pleckstrin
homology) and SH3 (Src homology 3) domain-containing Rho-
GAP] [8] and GRAF3 (G. Doherty, personal communication)
constitute a subfamily of structurally related regulatory proteins.
They share an N-terminal BAR (Bin/amphiphysin/Rvs)-like
domain,followedbyaPHdomainandaRhoGAP-relateddomain
(Figure 1A). Nadrin (Rich1, ARHGAP17) also has similar
architecturebutlacksthecentralPHdomainbetweentheBARand
the GAP domain [9]. The BAR domain superfamily of proteins
haveemergedasimportantplayersinmembrane-remodellingpro-
cesses(http://www.bar-superfamily.org).Thesedomainsdimerize
to sense, and often to induce, membrane curvature [10–12]. In
addition, the BAR domain of arfaptin2/POR1 (partner of Rac1)
has been reported to bind differently to ADP-ribosylation factors
and Rac1 [13].
Although the molecular mechanisms of Rho protein regulation
byGAPsarewellcharacterized[4],ourunderstandingoftheGAP
regulation itself is an open and challenging issue. Recently, we
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Figure 1 BAR-mediated autoinhibition of OPHN1 GAP activity
(A) Schematic representation of the BAR domain-containing regulators of Rho proteins and constructs used in the present study. Abbreviations not explained in the text are: P, proline-rich sequence;
pQ, polyglutamine sequence; SH3, Src homology 3 domain; STP, serine/threonine/proline-rich domain. (B) In contrast with GAPO or PH-GAPO, the BAR-PH-GAPO represents an autoinhibited state
of OPHN1, as it exhibited a strongly reduced GAP activity towards Cdc42·tamraGTP (0.2μM). The concentration of the GAP proteins was 1μM. The inset shows the complete time course of the
GTPase reaction in the absence (intrinsic; no GAP) or in the presence of BAR-PH-GAP. The observed rate constants (kobs) obtained by single exponential ﬁtting of the curves were 0.0031 s−1 for
the intrinsic reaction (no GAP), 0.18 s−1 for BAR-PH-GAPO,9 . 1s −1 for GAPO,8 . 6s −1 for PH-GAPO and 6.3 s−1 for the tryptic product of the BAR-PH-GAPO. Values represent the average of at least
ﬁvedifferentexperiments.(C)CoommassieBlue-stained SDSgelshowingpuriﬁedBAR-PH-GAPO proteinbefore(0 h)andafter (48h)trypticdigestion.Mstandsfor markerproteins,with molecular
massshownontheleft-handsideinkDa.(D)InhibitionoftheGAP-stimulatedtamraGTPhydrolysisreactionofCdc42(0.2 μM)wasmeasuredinthepresenceof0.5μMGAP O andvariousamounts
of the BAR-PHO domain (5–100μM). The IC50 value of 11.8μM was calculated by hyperbolic ﬁtting of the binding curves. (E) Calorimetric titration of 150μM BAR-PHO with 1500μMG A P O.
Fitting of the isothermal curve yielded a molar ratio of 0.87 and a Kd value of 21μM.
have found that the N-terminal region of OPHN1 seems to effect
its GAP function and suggested that this part of the protein itself
couldactasaregulatorofGAPactivityeitherbyanautoinhibitory
mechanism or by binding of a second inhibitory protein [14].
In the present study we investigated a potential role of the
N-terminal domains of GRAF1 and OPHN1 on their GAP
activities. We describe a novel function for the BAR domains
of the GRAF subfamily, which inhibit the activity of the GAP
domains and remodel simultaneously lipid membranes.
MATERIALS AND METHODS
Constructs
Human Cdc42 [aa (amino acids) 1–178; GenBank® accession
number NM_001791], Rac1 (aa 1–184; M29870) and RhoA (aa
1–181; L25080) were cloned as described previously [15]. BAR-
PH-GAP (aa 1–572), BAR-PH (aa 1–366), PH-GAP (aa 231–
572) and GAP (aa 360–572) of OPHN1 (NM_002547), BAR-
PH-GAP (aa 1–576), BAR-PH (aa 1–382) and GAP (aa 361–
576) of GRAF1 (Y10388), BAR-GAP (aa 1–499), BAR (aa 1–
241) and GAP (aa 245–499) of Rich1/nadrin (BC003259), BAR
(aa 116–341) of arfaptin2 (NM_012402), BAR (aa 1–256) of
endophilin-A1 (Q99962), GAP (aa 1250–1513) of p190RhoGAP
(M94721), GAP (aa 559–882) of ABR [active BCR (breakpoint
cluster region)-related gene] (L19704), GAP (aa 198–439) of
p50RhoGAP (NM_004308) and BAR-PH (aa 1–384) of β2-
centaurin (NP_055729) were cloned in pGEX vectors.
Proteins and ﬂuorescent nucleotides
All proteins were produced and prepared as described in [16].
Brieﬂy, the proteins were produced as GST (glutathione transfer-
ase) fusion proteins in Escherichia coli BL21 (DE3) or Rosetta
(DE3). GSH–Sepharose (Pharmacia) was used as the ﬁrst
puriﬁcation step. After protease cleavage of the GST tags, the
proteins were applied to a gel-ﬁltration column (Superdex 75 or
200, Pharmacia) and a subsequent GSH–Sepharose column as
the ﬁnal step to obtain a purity of at least 95%. Nucleotide-
free GTPases as well as ﬂuorescent nucleotide-bound GTPases
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were prepared, and concentration and quality were determined as
described in [16]. TamraGTP (tetramethylrhodamine-conjugated
GTP) was synthesized according to protocols previously
established in our laboratory [3,16].
Proteolytic cleavage
Puriﬁed BAR-PH-GAP was treated with trypsin at a protease/
substrate ratio of 1:4000 at room temperature (25◦C) for up to
48 h.Aliquotsfromtheproteolysisreactionwerewithdrawnatthe
indicated time points. The reaction was terminated with 50 μg/ml
leupeptin for the trypsin reaction. BAR-PH-GAP cleavage was
analysed on SDS/polyacrylamide gels.
Fluorescence measurements
The stopped-ﬂow instrument (Applied Photophysics SX18MV)
was routinely utilized for analysis of rapid kinetics, such as
GAP-stimulated GTPase reactions (single turnover conditions) as
describedin[16].Allﬂuorescencemeasurementswereperformed
in 30 mM Tris/HCl, pH 7.5, 10 mM KH2PO4/K2HPO4,1 0m M
MgCl2, 50 mM NaCl and 3 mM dithioerythritol at 25◦C.
Isothermal titration microcalorimetry
Titration experiments were carried out at 10◦C with the iso-
thermal titration microcalorimeter VP-ITC (isothermal titration
calorimetry) system (Microcal, Northampton, MA, U.S.A.). All
protein solutions were prepared in 20 mM Tris/HCl (pH 7.5) by
size-exclusion chromatography. The protein concentrations in the
calorimetric cell were between 50 and 400 μM. Injections of
ligand solution (1–3.5 mM)into thecalorimetric cellwerecarried
out at time intervals of 200 s with injection volumes of 8 μl. The
injectionvolumewas8 μl,exceptfortheﬁrststep(2 μl).Thetotal
number of injections was 60. Spacing time between injections
was 4 min. Analysis of the experimental data was carried out
with Origin 7.0 software (Microcal). Binding parameters such as
number of binding sites (n), the association constant (Ka)a n dt h e
binding enthalpy ( H◦) were determined as parameters of
the ﬁtted experimental binding values.
Liposome co-sedimentation assay
Liposomes were generated from total brain lipids (Folch frac-
tion I) (Sigma–Aldrich) or synthetic lipids [10% phosphatidyl-
inositol 4,5-bisphosphate, 10% cholesterol, 40% phospha-
tidylethanolamine, 40% phosphatidylcholine (Avanti Polar
Lipids)] and ﬁltered to the speciﬁed diameter as previously de-
scribed [10]. Brieﬂy, the lipid mixtures were dried under a stream
of nitrogen and resolved in assay buffer before sonication to
generatesphericalliposomes.Liposome-bindingassayswereper-
formed essentially as described in [10]. Brieﬂy, proteins were in-
cubated together with liposomes followed by centrifugation and
analysis of the pellet and supernatant on SDS/PAGE.
Transfection and membrane staining
HeLa cells were grown in DMEM (Dulbecco’s modiﬁed Eagle’s
medium) media (GIBCO) supplemented with 10% foetal bovine
serum, and transfected for transient protein expression using
Lipofectamine
TM 2000 (Invitrogen) according to the manufac-
turer’sinstructions.Forimmunoﬂuorescenceanalysis,HeLacells
were ﬁxed in 3% (w/v) paraformaldehyde in PBS for 15 min at
22◦C,thenwashedandblockedinPBScontaining5%goatserum
and0.1%saponinbeforestainingwithrabbitanti-Mycantibodies
(Cell Signaling Technology) in 1% goat serum, 0.1% saponin
in PBS and secondary Alexa Fluor® 488-conjugated anti-rabbit
antibodies (Invitrogen) using standard protocols. Epiﬂuorescence
images were taken using a Zeiss Axioimager Z1 system with
AxioVision software.
RESULTS AND DISCUSSION
BAR domain is a cis-acting inhibitory element
In a previous study, we found that full-length OPHN1 showed
a much weaker GAP activity compared with the GAP domain
alone when overexpressed in cells [14]. To investigate a potential
inhibitory mechanism for the catalytic GAP domain, we puriﬁed
various protein fragments of OPHN1 (Figure 1A) and deter-
mined their activities in a real-time ﬂuorescence-based GTP-
hydrolysis assay [3,16]. The central tool of this assay is a
tamraGTP, which is sensitive towards the active state of the Rho
proteins and thus can be used to monitor not only the intrinsic
but also the GAP-stimulated hydrolysis reactions. In contrast
with OPHN1 GAP (denoted GAP
O) and PH-GAP
O, which were
able to rapidly stimulate the intrinsic GTP-hydrolysis reaction of
Cdc42 to the same extent, the GAP activity of BAR-PH-GAP
O
wasdrasticallyreduced(50-fold,undertheconditionstestedhere;
Figure 1B). Similar results were obtained when RhoA or Rac1
were used (results not shown). We used Cdc42 as a model protein
for all experiments since GAP
O revealed the highest activity
towards Cdc42 when compared with that of RhoA and Rac1
(Supplementary Figure S1, at http://www.BiochemJ.org/bj/417/
bj4170371add.htm).
To prove that the drastic reduction of the BAR-PH-GAP
O
activity is caused by a speciﬁc domain–domain interaction rather
than by protein instability or misfolding, we subjected BAR-PH-
GAP
O to partial proteolysis. Two fragments of 24 and 22 kDa
remainedstableafterlimitedtrypsincleavagefor48 h(Figure1C;
Supplementary Figure S2A, at http://www.BiochemJ.org/bj/417/
bj4170371add.htm). Trypsin treatment of GAP
O or BAR-PH
O,
however,resultedinacompletedigestionofBAR-PH
O,butGAP
O
was cleaved to a 22 kDa fragment that remained resistant against
trypsin(SupplementaryFigureS2B).Acomparisonofthetrypsin
treatment of GAP
O and BAR-PH-GAP
O clearly indicated that
the tryptic products of the latter cover GAP
O, as it retained full
GAP activity (Figure 1B). Moreover, BAR-PH-GAP
O cleavage
at 30 min was signiﬁcantly reduced in comparison with BAR-
PH
O, which is entirely trypsinized after 15 min (Supplementary
Figure S2B). It appears that the presence of GAP
O in BAR-PH-
GAP
O protects BAR-PH
O against trypsin digestion. These results
provided the ﬁrst evidence for a domain–domain interaction
of OPHN1, indicating that BAR-PH-GAP
O exists in a ‘closed’
autoinhibited state, and tryptic degradation of BAR-PH
O allowed
the release of the autoinhibitory function.
Next we examined whether the autoinhibited state of OPHN1
can be reconstituted in vitro using isolated GAP
O and BAR-
PH
O. As shown in Figure 1(D), increasing amounts of BAR-PH
O
led to an incremental inhibition of the GAP-stimulated tamraGTP
hydrolysis of Cdc42, which is indicative of the direct association
between BAR-PH
O and GAP
O.A nI C 50 (concentration causing
50% inhibition of GAP activity) value of 11.8 μM was obtained
by hyperbolic ﬁtting of individual observed rate constants (kobs)
plotted against the BAR-PH
O concentrations used. Addition of
BAR-PH
O to GAP
O was able to reduce the GAP activity to a
level similar to that of BAR-PH-GAP
O. To validate this result, the
equilibriumdissociationconstant(Kd)fortheinteractionbetween
GAP
O and BAR-PH
O was determined to be 21.3 μMu s i n gI T C
(Figure 1E; see also Supplementary Figure S3, at http://www.
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Figure 2 Inhibitory activity of BAR domains of the OPHN1/GRAF1 BAR/GAP domains
(A) Comparison of GAP activities of different proteins from OPHN1, GRAF1 and nadrin. All catalytic fragments of GAPs have been used at 1 μM concentration and inhibitory BARN or BAR-PHO/G
domains were applied at 50μM concentration. (B) Inhibitory effect of different BAR domain-containing proteins on GAPO activity. Concentrations have been used as in (A). (C) Inhibitory effect of
different BAR domain-containing proteins on GAPG activity. Similar concentrations were used as in (A)a n d( B). (D) Inﬂuence of BAR-PHO on the activity of different GAP catalytic fragments from
p50RhoGAP, p190RhoGAP and ABR. All kobs values represent the average of 5–7 different experiments.
BiochemJ.org/bj/417/bj4170371add.htm). The difference be-
tween the Ki and Kd values is most probably based on different
temperatureconditions(seetheMaterialsandmethodssection).In
addition, a 1:1 stoichiometry was derived from the ITC curve for
this intermolecular interaction. On the basis of the recent dimeric
BARandBAR-PHstructures([11,18]andreferencestherein),this
result can also be interpreted as a 2:2 complex between BAR-PH
and GAP.
In summary, our results showed that OPHN1 exists in an
autoinhibited state that is characterized by physical interactions
between the BAR-PH and the GAP domains. As a consequence,
BAR-PH competitively interferes with complex formation be-
tween the GAP domain and cognate Rho protein (Cdc42·GTP
in this case), thereby inhibiting the stimulation of the GTP-
hydrolysisreaction.Thisresultaddsanovelfunctiontotherapidly
expanding knowledge of the BAR protein superfamily.
A conserved autoregulatory mechanism for the GRAF subfamily
GRAF proteins (GRAF1, 2 and 3) are BAR domain-containing
RhoGAPs from the same family as OPHN1 (Figure 1A). This
is why we have also examined the impact of the corresponding
GRAF1 BAR-PH (BAR-PH
G) on the activity of GAP
G. Similarly
to OPHN1, BAR-PH-GAP
G also resided in an autoinhibited state.
Its activity in stimulating GTP hydrolysis of Cdc42 was far below
that of GAP
G alone (Figure 2A). In addition, GAP
G activity was
also inhibited in vitro by rapidly mixing BAR-PH
G and GAP
G in
stopped-ﬂow experiments, although higher concentrations were
required to achieve an equal inhibition compared with OPHN1
(results not shown). The observed lower efﬁciency of GRAF1
inhibition is probably caused by a lower binding afﬁnity of BAR-
PH
G foritsGAP
G domain,asaquantitativeanalysisofBAR-PH
G-
mediated GAP
G inhibition revealed an IC50 value of 43.6 μM.
Titration of BAR-PH
G with GAP
G in ITC yielded an ap-
proximate Kd value of 111 μM for this bimolecular interaction
(Supplementary Figure S3). Our data showed that OPHN1 and
GRAF1 adopted an autoinhibited state that is provided by an
interaction between the BAR-PH and the GAP domains. This
novel mechanism is general for proteins in this subfamily.
In contrast with the BAR-PH-containing GRAF subfamily
members, stopped-ﬂow experiments with nadrin BAR-GAP
(BAR-GAP
N) revealed approximately the same activity as
measured for the isolated GAP
N domain (Figure 2A). Even a
50-fold molar excess of the isolated BAR
N above the GAP
N
concentration did not inhibit the GAP-stimulated tamraGTP
hydrolysisatall(Figure2A).Theseresultsledustotheconclusion
that BAR
N is unable to inactivate GAP
N and thus may not be
directly involved in the regulation of nadrin GAP activity. It is
alsoimportanttonotethatnadrinisnotasefﬁcientasOPHN1and
GRAF (Figure 2A). Comparison with other members of the Rho
family revealed that nadrin exhibited the highest GAP activity for
Rac1 (results not shown). Using tamraGTP hydrolysis by Rac1
and GAP
N,B A R
N and BAR-GAP
N (Supplementary Figure S4,
at http://www.BiochemJ.org/bj/417/bj4170371add.htm), we
could show that nadrin GAP activity is not regulated by the
N-terminal BAR domain.
There are two possible explanations for this ﬁnding. The ﬁrst
and perhaps most probable explanation for the lack of BAR-
mediated regulation of nadrin GAP activity may rely on the
nature of the BAR
N structure that is different from the classical
BAR domains [10,11,17]. Nadrin belongs to a subclass of BAR
domains that contain an N-terminal amphipathic helix (called
N-BAR), which works as functional unit to promote dimerization
andmembranecurvaturegeneration[18,19].Itisalsonecessaryto
notethatnadrinlacksthecentralPHdomainincontrastwithGAPs
of the GRAF subfamily (Figure 1A). Although the PH-GAP
O
showed no signiﬁcant change in GAP-stimulated hydrolysis (Fig-
ures 1B and 2A), the possibility that the PH domain might be
important for autoinhibition should not be excluded. The isolated
BAR domain of OPHN1 or GRAF1 could shed light on this
subject, but we have not been successful so far in preparing a
stable BAR domain of OPHN1 or GRAF1.
BAR-mediated GAP inhibition is highly speciﬁc
After we identiﬁed the BAR domain of OPHN1 and GRAF1
as an autoinhibitory element that potently suppresses the GAP
activity of these regulators, we next examined whether such an
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Figure 3 Simultaneous operation of membrane tubulation and GAP inhibitory functions
(A) Effect of lipid membranes on the autoinhibited state of OPHN1. Comparison of GAP activities of BAR-PH-GAPO measured in the absence (no lip) and presence (lip) of phosphatidylinositol
4,5-bisphosphate-enriched liposomes and liposomes generated from total brain lipids (brain lip). Values represent the average of at least ﬁve different experiments. (B–D) Coomassie Blue-stained
gelsofliposomeco-sedimentationassays.Indicatedproteins(4μM) wereincubatedwithliposomes(lip)orwithoutliposomes(nolip) for20minandcentrifuged,andthesupernatant(S)andpellet
(P) fractions were analysed by SDS/PAGE. Note that BAR-PHO (B–C), but not BAR-PHG or β2-centaurin BAR-PH (BARPHβ2)( C), speciﬁcally recruits the GAPO to the liposomes and that GAPO does
not inhibit membrane binding of the BAR-PHO domains in trans (C)o rcis (D). (E) Quantiﬁcation of experiments as shown in (D) using densitometry (n=4). The histogram shows percent of bound
protein, calculated as the amount of protein in the pellet divided by the sum of protein in the supernatant and pellet. Error bars represent S.D. (F) Membrane tubulation by BAR-PH-GAPO. Electron
micrograph of liposomes incubated in the presence (upper panel) or absence (lower panel) of protein. Note the lipid tubule created from spherical liposomes by the addition of BAR-PH-GAPO
(15μM); scale bar=0.1μm. (G) Confocal micrograph of HeLa cell expressing myc-tagged OPHN1 BAR-PH-GAP. Scale bar=10μm.
inhibitory activity is interchangeable among other BAR domains.
Toaddressthisquestion,wedeterminedthekobs valuesoftheGAP-
stimulated tamraGTP hydrolysis reaction of Cdc42 in the
presence of various BAR domains, including OPHN1, GRAF1,
nadrin, amphiphysin, arfaptin-2 and endophilin-A1. As shown
in Figure 2(B), GAP
O activity is exclusively inhibited by a 50-
fold molar excess of the BAR-PH
O. Even the closely homolog-
ousBAR-PH
G wasnotabletoreducetheGAP
O activity.Similarly,
BAR domains were not able to bind to GAP
G and inhibit its
stimulatory GTPase activity, except for BAR-PH
G and BAR-
PH
O (Figure 2C) that, most remarkably, appeared to be a more
potent inhibitor than BAR-PH
G itself. This result is consistent
with higher binding afﬁnity of BAR-PH
O for the GAP
O domain
and indicates that OPHN1 and GRAF1 autoregulation operates
through a similar molecular mechanism.
Another issue that we addressed was whether the BAR-
binding site of the GAP domain is speciﬁc among different
GAPs for the Rho family. Therefore we measured stimulation of
Cdc42-mediated tamraGTP hydrolysis by the catalytic domain
of p50GAP, p190GAP and ABR in the absence and in the pres-
ence of BAR-PH
O. Figure 2(D) shows that the activity of these
GAPs is not affected at all and emphasizes that the BAR
domain-mediated autoinhibition of OPHN1 is highly speciﬁc.
These results also indicate that the BAR–GAP interaction utilizes
signatures, which are selective for the GRAF subfamily of GAPs.
Simultaneous dual-site of action of the BAR domain
The next step of the investigation was to examine the impact
of lipid membrane on the autoinhibited state of these GAPs.
We repeated the real-time ﬂuorescence measurements of the
tamraGTP hydrolysis reaction of Cdc42 in the presence of
liposomes and lipid membranes of different size. Representative
results are shown in Figure 3(A). It is evident that the activity
of the autoinhibited BAR-PH-GAP was not altered at all. This
prompted us to address the question of whether the autoinhibited
state of OPHN1 inﬂuences membrane-binding and -tubulating
abilities of the BAR domain, which was reported previously
[10]. Using a liposome co-sedimentation assay, we found that
the GAP
O domain could be co-sedimented with the membranes if
BAR-PH
O was present, again showing the trans-interaction. The
robust binding of BAR-PH
O to liposomes both in the absence and
presence of GAP
O (Figures 3B and 3C) suggests that the trans-
interaction between these domains did not inhibit the membrane-
binding ability of the BAR-PH
O. GAP
O was also able to
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Figure 4 Conceptual models for BAR–GAP interaction of the GRAF protein family
Possible and probable binding modes of how the BAR domain of GRAF1 or OPHN1 binds to the GAP domain and inhibits its activity towards Rho protein (A) is illustrated schematically (B, C); see
the text for details. The dotted square indicates the membrane-binding region at the reverse site.
co-sedimentwithBAR-PH
G,buttoamuchlowerextentcompared
with BAR-PH
O (Figure 3C). This is in agreement with results
described above and again indicates that BAR-PH
G exhibits
a much weaker GAP-inhibitory effect. Similar results were
obtained using β2-centaurin BAR-PH as a control. To investigate
further whether membrane binding is inﬂuenced in the context of
autoinhibitedprotein,wecomparedtheliposome-bindingactivity
of BAR-PH
O and BAR-PH-GAP
O. As shown in Figure 3(D)
and 3(E), instead of an inhibitory action, the presence of the
GAP domain yielded an even higher amount of BAR-PH-GAP
O
bound to the liposomes compared with that of BAR-PH
O.T h i s
result shows that the presence of the GAP domain does not
perturb membrane binding but may facilitate the interaction of
the BAR domain with the lipid membrane. Moreover, BAR-PH-
GAP
O was also able to generate lipid tubules when incubated
together with liposomes (Figure 3F) and to localize to membrane
tubuleswhenoverexpressedincells(Figure3G).Thesedatashow
that BAR-PH
O domain was unaffected in its membrane-binding
and -tubulating activity, regardless of its interaction with the
C-terminal GAP domain. The BAR domain represents a dual-site
system,whichsimultaneouslyinteractswiththeGAPdomainand
the lipid vesicles. In addition, interaction between the GAP
and BAR domains seems to potentiate the BAR-mediated ability
of membrane binding and remodelling.
CONCLUSIONS
BAR domains recently took centre stage in their area because
of their function as membrane curvature-sensing and -stabilizing
protein modules [11,17,19–21]. Our work has uncovered a novel
autoinhibitory function for BAR domain-containing RhoGAPs of
the GRAF subfamily. This is a stringent control mechanism to
suppress efﬁciently and locally the GAP activity of GRAF pro-
teins. Similar autoregulatory modes have been implicated for
other RhoGAPs, including DLC1 (deleted in liver cancer 1)
and p50RhoGAP. Whereas the mechanism of the autoinhibitory
domain remained unknown for DLC1 [22], an N-terminal
Sec14/BCH (Bnip2 and Cdc42 GAP homology) domain has been
shown to be essential for the regulation of the GAP activity of
p50RhoGAP [23].
The present study has provided the ﬁrst evidence for dual-site
action of a BAR domain that exhibits simultaneously membrane-
andprotein-bindingcapabilitieswiththelatterbeinganinhibitory
function on GAPs of the GRAF subfamily. One of the most
crucial questions of how the BAR domain of GRAF1 or OPHN1
binds to the GAP domain and inhibits its activity (Figure 4A) still
remains a subject for further research. Biochemical data from the
present and other studies along with the structural determination
of BAR domain-containing proteins have shown that BAR-like
domains form elongated, banana-shaped, α-helical homodimers
in an antiparallel orientation [11]. Therefore intramolecular
interactions of a monomer or of a parallel dimer and even an
intermolecular head-to-tail dimer (Figure 4B) can be excluded.
The fact that the BAR domain directly inhibits the GAP-
stimulated GTPase reaction of Rho proteins supports the notion
that it may bind to the Rho-binding region of the GAP domain
and thus mask its catalytic residues, including the arginine ﬁnger
[24]. Moreover, it has been reported that BAR dimers bind
membranes electrostatically through their positively charged
concave surface [10]. But simultaneous interactions of the BAR
domain of OPHN1 with the membrane and the GAP domain
suggests that the GAP domain may bind to the convex surface of
a banana-shaped homodimer of the BAR domain. Accordingly,
an intramolecular interaction between the domains of one protein
or an intermolecular interaction between the domains across the
two proteins or a transmolecular interaction of one GAP domain
and two BAR domains are three alternative symmetrical binding
modes of how these domains approach one another (Figure 4C).
The latter model of an autoinhibited state supports the idea of
GAP-induced stabilization of the dimerization state of the BAR
domain.
The role of the BAR domain, in conjunction with other
domains including the PH domain, is to localize the dormant
autoinhibited GAP protein to the membrane. As we know now,
this is not sufﬁcient to release the GAP domain and induce GAP
activity. Thus an obvious next step of the investigation is to
understand the release mechanism of the autoinhibited state of
these GAPs. Additional interactions are likely to displace the
autoinhibiting BAR domain and to release the GAP domain for
speciﬁc binding to an adjacent Rho protein at the membrane. This
will drive the progression of cellular processes in which GAPs
of the GRAF subfamily are required, including dendritic spine
morphogenesis and axon growth [25]. Identiﬁcation of functional
modules that inhibit the GAP activity, however, was an important
ﬁrst step towards elucidating underlying cellular mechanism of
these critical regulators.
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Figure S1 Determination of the speciﬁcity of OPHN1 GAP domain
The GAP activity was measured in a HPLC assay as described in [1,2] using 70 μM GTP-bound G-proteins and 7 nM GAP.
Figure S2 Proteolytic cleavage of the OPHN1 protein fragments
(A) Time course of trypsin treatment of the autoinhibited BAR-PH-GAPO protein. Puriﬁed BAR-PH-GAPO was mixed with trypsin at a protease/substrate ratio of 1:4000 at 25◦C. Aliquots from the
proteolysis reaction mixture were withdrawn at the indicated time points and analysed by SDS/PAGE after termination of the reaction with 50 μg/ml leupeptin. (B) The effects of proteolytic digestion
by trypsin on various OPHN1 proteins. Partial cleavage of GAPO (24.6kDa) for 24 h resulted in a trypsin-resistant 22kDa fragment, whereas BAR-PHO (43.2kDa) is completely digested after
15 min. Trypsin treatment of BAR-PH-GAPO (66.8kDa) led to the fragments of 24 and 22kDa that correspond to the size of the GAP domain and its tryptic product. These proteins exhibit a similar
GAP activity as determined for the GAPO and PH-GAPO fragments (Figure 1B, main text). Arrowheads highlight tryptic products of the GAP, BAR-PH and BAR-PH-GAP proteins.
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Figure S3 BAR-PH-binding to the GAP domain determined by ITC
BAR-PH–GAP interactions were measured by titrating 150 μM BAR-PHO (A)o r3 4 0μM BAR-PHG (B) with 1500 μMG A P O (A) or 3400 μMG A P G (B). The data analysis program provided by
MicroCal was used to obtain the number of binding sites, n, the equilibrium association constant Ka (which is equal to [BAR-PH·GAP]/[BAR-PH]/[GAP] or 1/Kd), and the binding enthalpy of
binding  H◦ (lower panel). It is important to note that the conditions used for the GRAF1 ITC experiment were suboptimal and that the data obtained give only approximate values for the BAR-PH
interaction with the GAP. It was not possible to use higher GAPG concentrations than we already used. The binding isotherms corresponding to the data and the best-ﬁtted curve yielded Kd =21 and
111 μM, n=0.87 and 0.61 and  H◦=6.4 and 8.7 kcal/mol (1 kcal=4.184kJ) for the OPHN1 and GRAF1 domains respectively.
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Figure S4 The BAR-GAP fragment of nadrin is not inhibited
TheGAPactivitiesofBAR-GAPN (10μM)andGAPN (10μM)intheabsenceandinthepresence
ofBARN (50μM)onthetamraGTPasereactionofRac1(0.2μM)wasmeasuredunderthesame
conditionsasin Figures1(B)and 2 ofthemain text. Valuesrepresenttheaverageofat least ﬁve
different experiments.
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Figure S3 BAR-PH-binding to the GAP domain determined by ITC
BAR-PH–GAP interactions were measured by titrating 150 μM BAR-PHO (A)o r3 4 0μM BAR-PHG (B) with 1500 μMG A P O (A) or 3400 μMG A P G (B). The data analysis program provided by
MicroCal was used to obtain the number of binding sites, n, the equilibrium association constant Ka (which is equal to [BAR-PH·GAP]/[BAR-PH]/[GAP] or 1/Kd), and the binding enthalpy of
binding  H◦ (lower panel). It is important to note that the conditions used for the GRAF1 ITC experiment were suboptimal and that the data obtained give only approximate values for the BAR-PH
interaction with the GAP. It was not possible to use higher GAPG concentrations than we already used. The binding isotherms corresponding to the data and the best-ﬁtted curve yielded Kd =21 and
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